DAWN
Day One Biopharmaceuticals, Inc.
Key Financials
Operating Income
$-127750000
↑ 41.2%
Net Income
$-107322000
↓ 12.4%
Revenue
$158.2M
↑ 20.6%
Total Assets
$507.8M
↓ 12.9%
Shareholders' Equity
$441.2M
↓ 12.3%
Total Liabilities
$66.7M
↓ 16.7%
EPS (Diluted)
$-1.04
↓ 2.0%
Cash & Equivalents
$197.1M
↑ 57.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/14/2026 | View on SEC |
| 15-12G | 5/4/2026 | View on SEC |
| SCHEDULE 13D/A | 4/27/2026 | View on SEC |
| 4 | 4/27/2026 | View on SEC |
| 4 | 4/23/2026 | View on SEC |
| 4 | 4/23/2026 | View on SEC |
| 4 | 4/23/2026 | View on SEC |
| 4 | 4/23/2026 | View on SEC |
| 4 | 4/23/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DAWN |
| Company Name | Day One Biopharmaceuticals, Inc. |
| CIK | 1845337 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650 484-0899 |